AssetMark’s Telix Pharmaceuticals TLX Stock Holding History
Bought
Maintained
Sold
Other funds holding TLX
AssetMark's TLX Position: Q3 2026 in Review
AssetMark held its Telix Pharmaceuticals (TLX) position steady in Q3 2026 at 185 shares worth $2.03K. The position accounts for ﹤0.01% of the portfolio, ranked #3046.
AssetMark first reported a position in TLX in Q2 2025 and has held it in 6 quarters since. The position peaked at $2.13K in Q2 2026. 50 funds tracked by Wall St. Rank hold TLX as of Q3 2026.
- AssetMark held 185 shares of Telix Pharmaceuticals worth $2.03K as of Q3 2026.
- AssetMark left its Telix Pharmaceuticals share count unchanged in Q3 2026.
- Telix Pharmaceuticals made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3046 holding.
- AssetMark first reported a position in Telix Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
- AssetMark's Telix Pharmaceuticals position peaked at $2.13K in Q2 2026.
- 50 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.